On Thursday, Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $122.41 which represents a slight increase of $4.42 or 3.75% from the prior close of $117.99. The stock opened ...
The "Nucleic Acid Therapeutics CDMO Market Size, Share & Trends Analysis, 2024-2030" report has been added to ...
Since the FDA cleared Sarepta Thereapeutics' gene therapy for nearly all people with Duchenne, its stock price has tanked.
1d
Analyst Uy Ear from Mizuho Securities maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) and keeping the price ...
Prime Medicine's layoffs are part of a pattern. At least a half-dozen gene-editing companies have laid off staff in the past ...
Sarepta Therapeutics Inc (SRPT) Stock Price Reaches $120.4: What Factors Are Influencing This Level?
Sarepta Therapeutics Inc (SRPT) stock saw a modest uptick, ending the day at $120.4 which represents a slight increase of $1.64 or 1.38% from the prior close of $118.76. The stock opened at $119.91 ...
The Fort Worth Police honored the late Detective W. T. Wise on the anniversary of his death in 1884, recalling his heroic actions and legacy.
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $177.83, a high ...
Piper Sandler analyst Biren Amin maintained a Buy rating on Sarepta Therapeutics (SRPT – Research Report) today and set a price target of ...
Discover six innovative clinical-stage biotech companies fostering R&D in the Duchenne muscular dystrophy therapeutic space.
These two could become direct competitors relatively soon.
We recently published a list of the 7 Best Revenue Growth Stocks to Buy According to Analysts. In this article, we are going ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback